Ignite Creation Date:
2025-12-24 @ 11:33 PM
Ignite Modification Date:
2025-12-29 @ 9:10 PM
Study NCT ID:
NCT04300556
Status:
RECRUITING
Last Update Posted:
2025-11-14
First Post:
2020-03-06
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRĪ±)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Sponsor:
Eisai Inc.
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
MORAb-202-G000-201
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None